SCYNEXIS INC (SCYX) saw its loss narrow to $4.87 million, or $0.25 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $7.18 million, or $0.52 a share.
Revenue during the quarter was stable at $0.06 million, when compared with the previous year period.
Operating loss for the quarter was $6.02 million, compared with an operating loss of $7.21 million in the previous year period.
"In the first quarter of 2017, we continued to advance the development program for the oral formulation of SCY-078, our lead development program and the first representative of a novel triterpenoid antifungal family," said Marco Taglietti, M.D., president and chief executive officer of SCYNEXIS.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]